Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. | Monte Rosa ...

Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...

"Because Aurora-A stabilizes N-Myc against degradation, inhibiting the interaction could represent a promising approach for anticancer drug development and our finding that peptidomimetics can ...